NASDAQ$PRVA
Privia Health Group, Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Privia Health's financial performance for Q2 2021 reflected revenue growth and strategic investments.
Privia Health reported a revenue of $225.8 million for the second quarter of 2021, a 23.2% increase compared to the previous year. The company experienced an operating loss of $193.2 million and a net loss of $172.5 million, primarily due to non-cash stock compensation expenses related to its IPO. Excluding these expenses, non-GAAP adjusted net income was $10.4 million, or $0.09 per diluted share.
- Total revenue increased by 23.2% year-over-year, reaching $225.8 million.
- Operating loss was $193.2 million, impacted by IPO-related non-cash stock compensation expenses.
- Non-GAAP adjusted net income was $10.4 million, or $0.09 per diluted share, a 69.0% increase year-over-year.
- Key operating metrics showed strong growth, including a 30.3% increase in practice collections, a 33.7% increase in care margin, and a 43.0% increase in adjusted EBITDA.
Headline financials
Revenue & EPS history
Privia Health · Revenue · Quarterly
$226M
Revenue by segment
Privia Health · $417M total across 6 segments · Q3 2023
- FFS-patient care$246M—58.8%
- Capitated revenue$88.5M—21.2%
- Shared savings$33.5M—8.0%
- FFS-administrative services$29.8M—7.2%
- Care management fees (PMPM)$17.8M—4.3%
- Other revenue$2.03M—0.5%
Forward guidance
The Company is providing the following update to its full year 2021 guidance:
Tailwinds
- Implemented Providers: 2,850 to 2,900
- Attributed Lives: 730,000 to 750,000
- Practice Collections: $1,445 million to $1,465 million
- GAAP Revenue: $860 million to $880 million
- Adjusted EBITDA: $34 million to $38 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+3.5%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+1.3%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+28.3%
Q1 2022
Best reaction
-8.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -4.1% | -9.9% | |
| Q4 2025 | +9.9% | +4.9% | -11.6% | |
| Q3 2025 | -4.3% | -2.8% | -4.7% | |
| Q1 2025 | +7.3% | +4.2% | -0.6% | |
| Q4 2024 | +5.8% | +6.1% | -6.1% | |
| Q3 2024 | +0.7% | +6.7% | +0.1% | |
| Q2 2024 | +4.4% | +9.7% | +2.1% | |
| Q1 2024 | -4.7% | -4.3% | -9.1% | |
| Q4 2023 | +9.4% | +11.6% | -2.0% | |
| Q3 2023 | +9.7% | +9.0% | +6.0% | |
| Q2 2023 | +1.6% | -1.2% | -2.3% | |
| Q1 2023 | +7.3% | +7.2% | -8.3% | |
| Q4 2022 | +4.6% | +6.3% | +1.7% | |
| Q3 2022 | +5.3% | +6.2% | -9.7% | |
| Q2 2022 | +0.6% | -4.6% | +13.3% | |
| Q1 2022 | +28.3% | +25.1% | +41.0% | |
| Q4 2019 | -2.0% | +6.4% | -3.5% | |
| Q4 2021 | +3.3% | +7.5% | +10.4% | |
| Q3 2020 | +12.3% | +18.3% | -14.5% | |
| Q3 2021 | +12.3% | +18.3% | -14.5% | |
| Q2 2020 | -8.8% | -14.8% | -26.5% | |
| Q2 2021 | -8.8% | -14.8% | -26.5% | |
| Q4 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2021 | -1.1% | +0.9% | +39.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro